Oct
2026
Fiera Milano, Italy
Visit us
stand 16C8, Finished Dosage & Formulation

DERMAGO GmbH

Exhibitor at CPHI Milan 2026
About Us

We grant licensing rights for the self-developed generic approvals of Advantan/ Skinatan and Skinoren/Beloren. In addition, we grant exclusive licensing rights for our patent-protected product Veregen. https://www.dermago-group.com/en/skincare-en/ https://www.dermago-group.com/en/degode-en/ https://www.dermago-group.com/en/aresus-en/

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Germany
  • On CPHI since:
    2022
  • Employees:
    1 - 24
Company types
Consultancy
Distributor/Import Export
Licensee
Pharmaceutical company
Wholesale/Retail
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 16C8, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • BELOREN®

    Product BELOREN®

    • Generic version of Skinoren/Finacea (Leo Pharma/Bayer)
    • Molecule: Azelaic Acid • Market: L700 (ACNE VULGARIS) & L71 (ROSACEA) • Therapeutic Indications: Creme formulation indicated for mild to moderate acne vulgaris / gel formulation indicated for mild to moderate papular-p...
  • SKINATAN®

    Product SKINATAN®

    • Generic version of Advantan®, Bayer • Molecule: Methylprednisolone Aceponate 0.1 % (4th generation Topical Glucocorticoids)

    • Market: D7A (Plain Topical Corticosteroids) •Therapeutic Indications: Dermatitis, Atopic Dermatitis, Contact Dermatitis (indication differs for...
  • VEREGEN®

    Product VEREGEN®

    • Innovative originator herbal product • Molecule: Sinecatechins (extract from green tea leaves) •Therapeutic Indications: External anogenital warts caused by Human Papilloma Virus (Type 6 and 11)

    • Formulation: Ointment •Global in-market sales 2020: ~€11m / ~1...